Your Location：
Home >
Browse articles >
Xianglian Huazhuo Prescription Regulates GP73/PERK/ATF4 Signaling Pathway to Influence Endoplasmic Reticulum Stress and Ameliorate Chronic Atrophic Gastritis
XXXX | Updated：2026-09-11
Previous|Next

    • Xianglian Huazhuo Prescription Regulates GP73/PERK/ATF4 Signaling Pathway to Influence Endoplasmic Reticulum Stress and Ameliorate Chronic Atrophic Gastritis

    • “The Xianglian Huazhuo Formula activates the GP73/PERK/ATF4 signaling pathway to induce endoplasmic reticulum stress-induced cell apoptosis, providing a new strategy for the treatment of chronic atrophic gastritis.”
    • DU Pengli , GUO Yuxi , WANG Yican , JIN Ziqi , KANG Xin , JIA Xuemei , XU Weichao , CAI Yanru , YANG Qian
    • Chinese Journal of Experimental Traditional Medical Formulae Pages: 1-10(2026)

    • DOI： 10.13422/j.cnki.syfjx.20260538     

      CLC：

    • Revised：2026-03-06 ，

      Accepted：11 March 2026 ，

    Scan QR Code

  •  
  •  

  • AI Introduction

  • Full Text(HTML)

  • Figs( 7 ) Tabs( 5 )

  • References

  • Publication Info

  • Metrics

11

Views

3

Downloads

0

CSCD

Alert me when the article has been cited
Submit
Tools
  • BibTeXDownload
  • EndnoteDownload
  • RefMan Download
  • NoteExpressDownload
  • NoteFirstDownload

Related Articles

Hezhong Xiaopi Granules Regulate Ncln-CHOP Axis to Inhibit Endoplasmic Reticulum Stress and Reduce Gastric Mucosal Cell Apoptosis
Investigating Effect of Xianglian Huazhuo Prescription on Cell Cycle and Proliferation in Rats with Chronic Atrophic Gastritis Through TGF-β1/Smads Signaling Pathway
Effect of Xianglian Huazhuo Prescription on Hedgehog Signaling Pathway in Rats with Chronic Atrophic Gastritis
Mechanism of Xianglian Huazhuo Prescription Against Chronic Atrophic Gastritis Based on Network Pharmacology and Experimental Verification
Xianglian Huazhuo prescription Regulates Nrf2/NQO1/HO-1 Signaling Pathway to Affect Oxidative Stress in Treatment of Chronic Arophic Gastritis

Related Author

LI Hongzheng
WANG Shaoli
SHANG Zucheng
LI Mengfan
LIU Zhen
WANG Yican
WANG Jie
CHENG Yirui

Related Institution

Postdoctoral Research Center， China Academy of Chinese Medical Sciences
Guang'anmen Hospital， China Academy of Chinese Medical Sciences
Academy of Integrative Medicine，Fujian University of Traditional Chinese Medicine
The First Affiliated Hospital of Hebei University of Chinese Medicine
Hebei Key Laboratory of Turbidity Toxin Syndrome